Pomezia, Italy, June 1, 2018 - Menarini Ricerche (Menarini Group) will present at ASCO Annual Meeting 2018 the study design of CD205-Shuttle, a multicenter first-in-human clinical study to evaluate MEN1309/OBT076, an antibody drug conjugate (ADC) investigated for the treatment of metastatic solid tumors and non-Hodgkin’s lymphoma (NHL).

MEN1309/OBT076 is a fully humanized IgG1 monoclonal antibody, in co-development with Oxford BioTherapeutics (OBT), conjugated to a potent cytotoxic maytansinoid toxin via a cleavable linker. The ADC is directed against a type I transmembrane glycoprotein CD205/Ly75, that is over-expressed in several solid tumors and NHL.

The poster “CD205-Shuttle study: A first-in-human trial of MEN1309/OBT076 an ADC targeting CD205 in solid tumor and NHL” focused on the innovative design of the dose-escalation study will be presented during the session “Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics” Abstract no. TPS2606, on June 4, 2018 between 8:00 AM-11:30 AM at the McCormick Place Convention Center in Chicago, Illinois.

The CD205-Shuttle study is ongoing in major European oncology centers in Italy, Spain, Belgium and the UK. The study investigated to date 5 dose levels. The sixth dose level is currently being evaluated.